asparagine and Granulocytic Leukemia, Chronic

asparagine has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bouscary, D; Coiteux, V; Dekiouk, S; Fovez, Q; Germain, N; Ghesquiere, B; Idziorek, T; Jean-Pierre, S; Joncquel, M; Khamari, R; Kluza, J; Laine, W; Maboudou, P; Maguer-Satta, V; Mahon, FX; Marchetti, P; Quesnel, B; Trinh, A; Turcq, B	1

Other Studies

1 other study(ies) available for asparagine and Granulocytic Leukemia, Chronic

Article	Year
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 2022, Volume: 55 Topics: Animals; Apoptosis; Asparaginase; Asparagine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2022

Article

Year

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism, 2022, Volume: 55

Topics: Animals; Apoptosis; Asparaginase; Asparagine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases

2022